NASDAQ:IBRX ImmunityBio 11/8/2023 Earnings Report $2.70 +0.06 (+2.27%) Closing price 07/3/2025 03:49 PM EasternExtended Trading$2.70 0.00 (0.00%) As of 07/3/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast ImmunityBio EPS ResultsActual EPS-$0.19Consensus EPS -$0.27Beat/MissBeat by +$0.08One Year Ago EPSN/AImmunityBio Revenue ResultsActual Revenue$0.08 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmunityBio Announcement DetailsQuarterDate11/8/2023TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsImmunityBio's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Friday, August 8, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile ImmunityBio Earnings HeadlinesImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial SuccessJuly 2 at 7:52 AM | msn.comImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVAJune 24, 2025 | msn.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 5 at 2:00 AM | Crypto 101 Media (Ad)ImmunityBio: Lymphopenia Opportunity Could Provoke Short SqueezeJune 12, 2025 | seekingalpha.comImmunityBio (IBRX) Jumps 18% on Anktiva Access ExpansionJune 10, 2025 | msn.com15 Stocks That Stole The Show Last WeekJune 8, 2025 | insidermonkey.comSee More ImmunityBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email. Email Address About ImmunityBioImmunityBio (NASDAQ:IBRX) is a clinical-stage biotechnology company dedicated to developing targeted immunotherapies for cancer and infectious diseases. The company leverages a proprietary platform of natural killer (NK) cell and T-cell therapies, oncolytic adenovirus technology and an Artificial Intelligence RNA (AiR) mRNA platform to stimulate and enhance the body’s immune response. ImmunityBio’s research focuses on multiplexed approaches designed to overcome tumor microenvironment resistance and drive more durable clinical responses. The company’s pipeline includes several lead product candidates across solid tumors and viral diseases. Its NK-cell therapy programs are engineered to persist and expand in vivo, offering potential treatment options for indications such as head and neck cancer, non-small cell lung cancer and melanoma. Complementing cell therapies, ImmunityBio’s oncolytic adenovirus platform delivers immune-activating cytokines directly to tumor sites, while its AiR mRNA vaccine technology is being applied to both emerging infectious diseases and oncology settings. Founded in 2014 under the name NantKwest and rebranded as ImmunityBio in 2021, the company is headquartered in Culver City, California. ImmunityBio was established by entrepreneur and physician Patrick Soon-Shiong, who serves as Executive Chairman. Under his leadership, the company has built collaborations with academic institutions and government agencies, including the U.S. National Institutes of Health, to advance clinical trials and co-develop next-generation immunotherapies. ImmunityBio conducts its research and clinical programs primarily in the United States but has extended its footprint through international studies in South Africa and Asia. With a multidisciplinary leadership team of immunologists, oncology researchers and biomanufacturing experts, the company aims to translate scientific innovation into scalable treatments that address unmet medical needs across diverse patient populations.Written by Jeffrey Neal JohnsonView ImmunityBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
